An observational study in Chromosomal Aneuploidies (e.g., Trisomy 21, Trisomy 18, Trisomy 13); Prenatal Screening Accuracy, sponsored by Haseki Training and Research Hospital. Active, not recruiting at 1 site in Turkey (Türkiye). Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by Haseki Training and Research Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Down Syndrome with a site in Turkey — 1 open to participants now, 2 under way, none of them phase 3. Down Syndrome · Turkey.
Among the 19 studies in Down Syndrome with a site in Turkey, this one is one of 3 that started in 2025, is one of 6 observational ones, and was the 16th registered.
439 studies on the registry are indexed under Down Syndrome; 99 are open to participants now.
Browse Down Syndrome studies →1 of the 19 studies in Down Syndrome with a site in Turkey is open now. Recruiting first, the newest first:
Izgi Miray Demirbag · Sites in Turkey
Ages 4 mo–12 mo
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 74 Down Syndrome studies recruiting now, 14 (19%) set no upper age limit and 57 (77%) stop at 75 or younger; 60 take children under 18; 19 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2025.
This study's planned enrollment of 270 is above the median of 158 across 145 observational studies indexed under Down Syndrome.
Median enrollment 34 across the 13 interventional studies, 63 across the 6 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 19 has an industry lead sponsor. The 10 most frequent:
Haseki Training and Research Hospital is the lead sponsor of 78 studies on the registry; 17 are open to participants now.
Haseki Training and Research Hospital has 1 study filed under Down Syndrome — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Down Syndrome with a site in Turkey, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Template-Based Brief Summary (Sağlık Profesyonelleri İçin)
Study Title:
The Negative Predictive Value of First-Trimester Fetal Bladder "Rapid Emptying" (≤40 minutes and post-void ≤2 mm) for Major Chromosomal Aneuploidies: A Prospective Diagnostic Accuracy Study.
Purpose:
To evaluate whether the dynamic phenotype of rapid bladder emptying at 11-14 weeks reduces the likelihood of major chromosomal abnormalities (particularly Trisomy 21) compared to fetuses without this phenotype.
Design:
Single-center, prospective observational cohort.
Population:
270 singleton pregnancies between 11+0 and 14+0 weeks.
Procedures:
Real-time sagittal ultrasound observation for 40 minutes.
Documentation of bladder emptying time and post-void longitudinal bladder diameter.
Concurrent measurement of CRL, NT, ductus venosus waveform.
Gold standard confirmation with cfDNA or invasive karyotyping in high-risk cases.
Primary Endpoint:
Negative predictive value (NPV), ROC-AUC, sensitivity/specificity for aneuploidy detection.
Secondary Endpoints:
Rate of invasive testing, performance in combined models with cfDNA and biophysical markers, Net Reclassification Index.
Duration:
5 months (08/2025 - 01/2026).
Potential Impact:
If validated, the rapid emptying phenotype may serve as a low-risk marker, reduce unnecessary invasive procedures, and refine first-trimester screening algorithms.
Prospective cohort of 270 consecutive healthy pregnant women with singleton fetuses, attending first-trimester screening (11 - 14 GA) at a tertiary perinatology center in Istanbul, Türkiye.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: 40-Minute Real-Time First-Trimester Ultrasonography
Diagnostic Test: 40-Minute Real-Time First-Trimester Ultrasonography
A one-time midsagittal ultrasound performed between 11 +0 and 14 +0 weeks. Bladder emptying time and post-void longitudinal bladder diameter are recorded. No invasive procedures are performed.
Negative Predictive Value (NPV) of Rapid Fetal Bladder Emptying for Detecting Major Chromosomal Aneuploidy
Proportion of fetuses with the rapid-emptying phenotype (≤ 40-minute complete emptying + post-void longitudinal bladder diameter ≤ 2 mm) who are subsequently confirmed not to have a major chromosomal aneuploidy (Trisomy 21, 18, or 13) by cfDNA, invasive karyotype, or postnatal testing.
Time frame: From enrollment at 11 + 0 to 14 + 0 gestational weeks until definitive genetic result or delivery, whichever comes first (≈ 26 weeks).
Plan to share: Yes — De-identified individual participant data (IPD) underlying the primary and secondary outcome analyses-including fetal bladder emptying time, post-void longitudinal bladder diameter, nuchal translucency, ductus venosus waveform, cfDNA results, and karyotype confirmation-will be shared with qualified researchers upon reasonable request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: De-identified IPD, çalışma protokolü, SAP ve boş ICF; ana sonuçların hakemli dergide yayımlanmasından itibaren 12 ay içinde erişime açılacak ve 5 yıl süreyle paylaşılabilir olacaktır (yaklaşık Temmuz 2027 - Temmuz 2032).
Started Aug 2025 (actual). Primary completion is estimated for Oct 2025, 2 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Haseki Training and Research Hospital